February 13, 2006 09:09 ET

(OTC: TEDG) Signs Letter of Intent to Acquire China BioPharma Limited

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit.

LAKE HARMONY, PA -- (MARKET WIRE) -- February 13, 2006 -- The IO Circuit recommends Techedge, Inc. (OTC BB: TEDG), which announced that it has signed a Letter of Intent to acquire China BioPharma Limited, a Cayman Island company, which has the rights to have majority ownership in one of the largest non-government owned vaccine manufactures in China.

"We are very excited about this potential acquisition. With the largest population in the world, the demand for vaccines of epidemic and common diseases is growing significantly in China. This is the first major step since we've recently repositioned our business and strategy to focus at opportunities in the fast growing bio-pharmaceutical, information, and media sectors in China," stated Peter Wang, President and CEO of Techedge.

For more information, go to

Other active stocks are Generex Biotechnology Corp. (NASDAQ: GNBT), Gilat Satellite Networks Ltd. (NASDAQ: GILTF) and SteelCloud Inc. (NASDAQ: SCLD).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $695.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information